Pacer Advisors Inc. Has $638,000 Stock Position in Solventum Corporation $SOLV

Pacer Advisors Inc. reduced its position in shares of Solventum Corporation (NYSE:SOLV) by 43.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,763 shares of the company’s stock after selling 7,386 shares during the quarter. Pacer Advisors Inc.’s holdings in Solventum were worth $638,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its stake in shares of Solventum by 46.6% during the first quarter. Parallel Advisors LLC now owns 4,019 shares of the company’s stock worth $262,000 after buying an additional 1,277 shares during the last quarter. NewEdge Advisors LLC boosted its stake in Solventum by 2.2% in the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after acquiring an additional 144 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Solventum during the 1st quarter worth $230,000. Wellington Grp LLC grew its holdings in Solventum by 48.7% during the 1st quarter. Wellington Grp LLC now owns 6,561 shares of the company’s stock worth $428,000 after acquiring an additional 2,150 shares during the period. Finally, Western Wealth Management LLC bought a new stake in shares of Solventum during the 1st quarter valued at $58,000.

Analyst Ratings Changes

Several research analysts have recently issued reports on SOLV shares. Stifel Nicolaus raised their price target on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. BMO Capital Markets initiated coverage on Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. KeyCorp raised their target price on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Mizuho set a $113.00 target price on Solventum in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $91.64.

Solventum Stock Up 2.9%

Solventum stock opened at $85.38 on Tuesday. The company has a 50 day moving average of $79.58 and a 200-day moving average of $74.45. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $90.00. The stock has a market capitalization of $14.53 billion, a PE ratio of 10.44, a price-to-earnings-growth ratio of 1.06 and a beta of 0.60.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. During the same period last year, the business posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 7.25 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.